Overview

A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants

Status:
Completed
Trial end date:
2018-08-22
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the effect of itraconazole and rifampin on how fast selpercatinib gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study is conducted in two parts and it will last up to 54 days (part 1) and 59 days (part 2), respectively, inclusive of screening period.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Loxo Oncology, Inc.
Treatments:
Itraconazole
Rifampin